Clinical Trial Update: Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA [Phase 3]

View source ↗

Summary

Phase 3 trial updating immunogenicity and safety of a HBVAXPRO challenge dose in healthy children previously vaccinated with HEXAVAC or INFANRIX HEXA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HBVaxPro (Hepatitis B surface antigen, recombinant)
• Hexavac (DTPa-HBV-IPV-Hib hexavalent vaccine)
• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Virus Diseases, Hepatitis B | Phase 3 | Status: COMPLETED